摘要
目的在进行耐药结核病治疗时,对应用利奈唑胺治疗发生的不良反应情况进行研究。方法此研究对象为2019年1月-2021年12月收治的耐药结核病患者,所有患者均应用利奈唑胺治疗,在出现不良反应患者中抽选出54例,利用统计学软件对患者各项数据进行分析。结果出现不良反应的54例患者中男性占比40.74%,女性占比59.26%;61-80岁患者发生不良反应占比最高,为48.15%;不良反应患者中起始剂量为600mg·qd、600mg·bid,分别有8例、46例。利奈唑胺发生不良反应累及神经系统、血液系统、消化系统、皮肤及其附件,总次数为67次,其中600mg·qd占比为26.87%;而600mg·bid占比为73.13%。在发生的67次不良反应中,出现了呕吐症状、周围神经炎。其中,19例进行血药浓度监测,监测患者占比35.19%。结论在进行耐药结核病治疗的过程中,必须对不良反应情况进行控制,因此,需要对患者血药浓度和不良反应进行监测,在保障治疗效率的同时确保安全用药。
Objective To investigate the adverse drug reactions(adrs)associated with the use of Linezolid in the treatment of drugresistant tuberculosis.Methods All patients with drug-resistant tuberculosis were enrolled in this study from January 2019 to December 2021.All patients were treated with Linezolid.Adverse drug reactions in 54 patients,the data of patients were analyzed by statistical software.Resul ts The rate of adverse drug reactions was 40.74%in male and 59.26%in female,the highest rate of adverse drug reactions was 48.15%in 61-80 years old,the initial dose was 600mg:qd and 600mg·bid in 8 and 46 patients respectively.The total number of adverse Linezolid involving the nervous system,blood system,digestive system,skin and its appendages was 67,of which 600mg·qd accounted for 26.87%and 600mg·bid for 73.13%.Among the 67 adverse reactions,vomiting and peripheral neuritis occurred.Among them,19 cases were monitored,the monitoring patients accounted for 35.19%.Conclusion In the course of treatment of drug-resistant tuberculosis,it is necessary to control the adverse reaction.Therefore,it is necessary to monitor the drug concentration in patients'blood and the adverse reaction,to ensure the efficiency of treatment while ensuring the safety of drug use.
作者
李勇
Li Yong(Tanggu Infectious Disease Hospital,Binhai New Area,Tianjin 300450,China)
出处
《首都食品与医药》
2023年第7期73-75,共3页
Capital Food Medicine
关键词
利奈唑胺
耐药结核病
治疗
不良反应
Linezolid
Drug-resistant tuberculosis
treatment
Adverse reactions
